SIGNET RING CELL ADENOCARCINOMA
Clinical trials for SIGNET RING CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SIGNET RING CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for SIGNET RING CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virus and immunotherapy combo shows promise for Tough-to-Treat skin cancers
Disease control OngoingThis study is testing a two-step treatment for people with rare skin cancers or certain lymphomas that have not responded to standard therapies. First, patients receive a virus-based drug (talimogene laherparepvec) injected directly into tumors. Then, they also get an immunothera…
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Could a chemo-immunotherapy combo tame hard-to-treat colorectal cancer?
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to a standard chemotherapy (Nordic FLOX) can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). These types usually don't respond well to i…
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC